{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:47:29Z","timestamp":1760143649191,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science for Peace and Security (SPS) NATO Programme","award":["SPS G5937"],"award-info":[{"award-number":["SPS G5937"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The continuous emergence of SARS-CoV-2 variants caused the persistence of the COVID-19 epidemic and challenged the effectiveness of the existing vaccines. The viral proteases are the most attractive targets for developing antiviral drugs. In this scenario, our study explores the use of HIV-1 protease inhibitors against SARS-CoV-2. An in silico screening of a library of HIV-1 proteases identified four anti-HIV compounds able to interact with the 3CLpro of SARS-CoV-2. Thus, in vitro studies were designed to evaluate their potential antiviral effectiveness against SARS-CoV-2. We employed pseudovirus technology to simulate, in a highly safe manner, the adsorption of the alpha (\u03b1-SARS-CoV-2) and omicron (\u03bf-SARS-CoV-2) variants of SARS-CoV-2 and study the inhibitory mechanism of the selected compounds for cell\u2013virus interaction. The results reported a mild activity against the viral proteases 3CLpro and PLpro, but efficient inhibitory effects on the internalization of both variants mediated by cathepsin B\/L. Our findings provide insights into the feasibility of using drugs exhibiting antiviral effects for other viruses against the viral and host SARS-CoV-2 proteases required for entry.<\/jats:p>","DOI":"10.3390\/v16030338","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T08:34:35Z","timestamp":1708590875000},"page":"338","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-2"],"prefix":"10.3390","volume":"16","author":[{"given":"Davide","family":"Gentile","sequence":"first","affiliation":[{"name":"Department of Chemistry, Materials and Chemical Engineering \u201cG. Natta\u201d, Politecnico di Milano, Via Mancinelli 7, 20131 Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-9138","authenticated-orcid":false,"given":"Lucia","family":"Chiummiento","sequence":"additional","affiliation":[{"name":"Department of Scienze, University of Basilicata, Viale dell\u2019Ateneo Lucano 10, 85100 Potenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Santarsiere","sequence":"additional","affiliation":[{"name":"Department of Scienze, University of Basilicata, Viale dell\u2019Ateneo Lucano 10, 85100 Potenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1104-3439","authenticated-orcid":false,"given":"Maria","family":"Funicello","sequence":"additional","affiliation":[{"name":"Department of Scienze, University of Basilicata, Viale dell\u2019Ateneo Lucano 10, 85100 Potenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-041X","authenticated-orcid":false,"given":"Paolo","family":"Lupattelli","sequence":"additional","affiliation":[{"name":"Department of Chimica, Sapienza University of Roma, p. le Aldo Moro 5, 00185 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5039-2151","authenticated-orcid":false,"given":"Antonio","family":"Rescifina","sequence":"additional","affiliation":[{"name":"Department of Drug and Health Sciences, University of Catania, V. le A. Doria, 95125 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-1724","authenticated-orcid":false,"given":"Assunta","family":"Venuti","sequence":"additional","affiliation":[{"name":"International Agency for Research on Cancer (IARC), World Health Organization, 69366 LYON CEDEX 07, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6004-5196","authenticated-orcid":false,"given":"Anna","family":"Piperno","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-7724","authenticated-orcid":false,"given":"Maria Teresa","family":"Sciortino","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3474-6057","authenticated-orcid":false,"given":"Rosamaria","family":"Pennisi","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 Variants, Spike Mutations and Immune Escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The Evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1038\/s41467-023-38435-3","article-title":"Virological Characteristics of the SARS-CoV-2 XBB Variant Derived from Recombination of Two Omicron Subvariants","volume":"14","author":"Tamura","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Amin, S.A., Banerjee, S., Ghosh, K., Gayen, S., and Jha, T. (2021). Protease Targeted COVID-19 Drug Discovery and Its Challenges: Insight into Viral Main Protease (Mpro) and Papain-like Protease (PLpro) Inhibitors. Bioorg. Med. Chem., 29.","DOI":"10.1016\/j.bmc.2020.115860"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging Coronaviruses: Genome Structure, Replication, and Pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12985-020-01457-0","article-title":"Analysis of the Efficacy of HIV Protease Inhibitors against SARS-CoV-2\u2032s Main Protease","volume":"17","author":"Mahdi","year":"2020","journal-title":"Virol. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In Vitro Susceptibility of 10 Clinical Isolates of SARS Coronavirus to Selected Antiviral Compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J. Clin. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1080\/07391102.2020.1768151","article-title":"Identification of Potential Molecules against COVID-19 Main Protease through Structure-Guided Virtual Screening Approach","volume":"39","author":"Mittal","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1021\/acs.biochem.0c00160","article-title":"Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms","volume":"59","author":"Nutho","year":"2020","journal-title":"Biochemistry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of Lopinavir\/Ritonavir in the Treatment of SARS: Initial Virological and Clinical Findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Citarella, A., Dimasi, A., Moi, D., Passarella, D., Scala, A., Piperno, A., and Micale, N. (2023). Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives. Biomolecules, 13.","DOI":"10.20944\/preprints202308.0055.v1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"abe0751","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and Inhibition of the SARS-CoV-2 Main Protease Reveal Strategy for Developing Dual Inhibitors against Mpro and Cathepsin L.","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_16","first-page":"1586","article-title":"Distinct Conformational States of SARS-CoV-2 Spike Protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science (1979)"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Cell Editorial Team (2020). Embracing the Landscape of Therapeutics. Cell, 181, 1\u20133.","DOI":"10.1016\/j.cell.2020.03.025"},{"key":"ref_18","unstructured":"Hoffmann, M., Hofmann-Winkler, H., and P\u00f6hlmann, S. (2018). Activation of Viruses by Host Proteases, Springer International Publishing."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Xiang, Q., Li, L., Wu, J., Tian, M., and Fu, Y. (2022). Application of Pseudovirus System in the Development of Vaccine, Antiviral-Drugs, and Neutralizing Antibodies. Microbiol. Res., 258.","DOI":"10.1016\/j.micres.2022.126993"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Salazar-Garc\u00eda, M., Acosta-Contreras, S., Rodr\u00edguez-Mart\u00ednez, G., Cruz-Rangel, A., Flores-Alanis, A., Pati\u00f1o-L\u00f3pez, G., and Luna-Pineda, V.M. (2022). Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.817200"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gentile, D., Patamia, V., Scala, A., Sciortino, M.T., Piperno, A., and Rescifina, A. (2020). Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study. Mar. Drugs, 18.","DOI":"10.20944\/preprints202003.0372.v1"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"W442","DOI":"10.1093\/nar\/gkw287","article-title":"Pharmit: Interactive Exploration of Chemical Space","volume":"44","author":"Sunseri","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1016\/j.bmc.2017.07.014","article-title":"Synthesis and Biological Evaluation in Vitro and in Mammalian Cells of New Heteroaryl Carboxyamides as HIV-Protease Inhibitors","volume":"25","author":"Funicello","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"D\u2019Orsi, R., Funicello, M., Laurita, T., Lupattelli, P., Berti, F., and Chiummiento, L. (2021). The Pseudo-Symmetric N-Benzyl Hydroxyethylamine Core in a New Series of Heteroarylcarboxyamide HIV-1 Pr Inhibitors: Synthesis, Molecular Modeling and Biological Evaluation. Biomolecules, 11.","DOI":"10.20944\/preprints202109.0375.v1"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Millet, J., and Whittaker, G. (2016). Murine Leukemia Virus (MLV)-Based Coronavirus Spike-Pseudotyped Particle Production and Infection. Bio Protoc., 6.","DOI":"10.21769\/BioProtoc.2035"},{"key":"ref_28","first-page":"e59010","article-title":"Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting","volume":"145","author":"Millet","year":"2019","journal-title":"J. Vis. Exp."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1039\/C9OB02352F","article-title":"Cucurbit[7]Uril as a Catalytic Nanoreactor for One-Pot Synthesis of Isoxazolidines in Water","volume":"18","author":"Gentile","year":"2020","journal-title":"Org. Biomol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Floresta, G., Amata, E., Barbaraci, C., Gentile, D., Turnaturi, R., Marrazzo, A., and Rescifina, A. (2018). A Structure- and Ligand-Based Virtual Screening of a Database of \u201cSmall\u201d Marine Natural Products for the Identification of \u201cBlue\u201d Sigma-2 Receptor Ligands. Mar. Drugs, 16.","DOI":"10.3390\/md16100384"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gentile, D., Floresta, G., Patamia, V., Chiaramonte, R., Mauro, G.L., Rescifina, A., and Vecchio, M. (2020). An Integrated Pharmacophore\/Docking\/3D-QSAR Approach to Screening a Large Library of Products in Search of Future Botulinum Neurotoxin a Inhibitors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249470"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cmdc.201900594","article-title":"Repurposing of FDA-Approved Drugs for Treating Iatrogenic Botulism: A Paired 3D-QSAR\/Docking Approach","volume":"15","author":"Floresta","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/jcc.10349","article-title":"A Point-charge Force Field for Molecular Mechanics Simulations of Proteins Based on Condensed-phase Quantum Mechanical Calculations","volume":"24","author":"Duan","year":"2003","journal-title":"J. Comput. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/prot.21123","article-title":"Comparison of Multiple Amber Force Fields and Development of Improved Protein Backbone Parameters","volume":"65","author":"Hornak","year":"2006","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A Smooth Particle Mesh Ewald Method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hoffmann, M., Hofmann-Winkler, H., Smith, J.C., Kr\u00fcger, N., Arora, P., S\u00f8rensen, L.K., S\u00f8gaard, O.S., Hasselstr\u00f8m, J.B., Winkler, M., and Hempel, T. (2021). Camostat Mesylate Inhibits SARS-CoV-2 Activation by TMPRSS2-Related Proteases and Its Metabolite GBPA Exerts Antiviral Activity. EBioMedicine, 65.","DOI":"10.1016\/j.ebiom.2021.103255"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Pennisi, R., Gentile, D., Rescifina, A., Napoli, E., Trischitta, P., Piperno, A., and Sciortino, M.T. (2023). An Integrated In Silico and In Vitro Approach for the Identification of Natural Products Active against SARS-CoV-2. Biomolecules, 14.","DOI":"10.3390\/biom14010043"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12985-021-01624-x","article-title":"Keep out! SARS-CoV-2 Entry Inhibitors: Their Role and Utility as COVID-19 Therapeutics","volume":"18","author":"Chitsike","year":"2021","journal-title":"Virol. J."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Metzdorf, K., Jacobsen, H., Greweling-Pils, M.C., Hoffmann, M., L\u00fcddecke, T., Miller, F., Melcher, L., Kempf, A.M., Nehlmeier, I., and Bruder, D. (2023). TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection. Viruses, 15.","DOI":"10.3390\/v15020271"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"12920","DOI":"10.1038\/s41598-022-17082-6","article-title":"Robust Antiviral Activity of Commonly Prescribed Antidepressants against Emerging Coronaviruses: In Vitro and in Silico Drug Repurposing Studies","volume":"12","author":"Kutkat","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1473-3099(23)00118-4","article-title":"Effectiveness of Nirmatrelvir\u2013Ritonavir in Preventing Hospital Admissions and Deaths in People with COVID-19: A Cohort Study in a Large US Health-Care System","volume":"23","author":"Lewnard","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and Discovery of Its Inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity","volume":"65","author":"Shen","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.ijbiomac.2022.10.017","article-title":"A Decennary Update on Diverse Heterocycles and Their Intermediates as Privileged Scaffolds for Cathepsin B Inhibition","volume":"222","author":"Saroha","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41421-022-00419-w","article-title":"Novel Cleavage Sites Identified in SARS-CoV-2 Spike Protein Reveal Mechanism for Cathepsin L-Facilitated Viral Infection and Treatment Strategies","volume":"8","author":"Zhao","year":"2022","journal-title":"Cell Discov."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/338\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:57Z","timestamp":1760104977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["v16030338"],"URL":"https:\/\/doi.org\/10.3390\/v16030338","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}